Praxis Precision Medicines (Praxis Precision Medicines) ROCE % : -137.20% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Praxis Precision Medicines ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Praxis Precision Medicines's annualized ROCE % for the quarter that ended in Dec. 2023 was -137.20%.

Praxis Precision Medicines ROCE % Historical Data

The historical data trend for Praxis Precision Medicines's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Praxis Precision Medicines ROCE % Chart

Praxis Precision Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-128.83

-37.75

-61.77

-128.31

-165.21

Praxis Precision Medicines Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-175.74	-204.17	-157.54	-102.58	-137.20

Praxis Precision Medicines ROCE % Calculation

Praxis Precision Medicines's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-126.373	/	( ( (115.128 - 34.345)	+	(87.948 - 15.749) )	/ 2 )
	=	-126.373	/	( (80.783	+	72.199)	/ 2 )
	=	-126.373	/	76.491
	=	-165.21 %

Praxis Precision Medicines's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-111.224	/	( ( (106.725 - 16.792)	+	(87.948 - 15.749) )	/ 2 )
	=	-111.224	/	( ( 89.933	+	72.199 )	/ 2 )
	=	-111.224	/	81.066
	=	-137.20 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Praxis Precision Medicines (NAS:PRAX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Praxis Precision Medicines ROCE % Related Terms

Thank you for viewing the detailed overview of Praxis Precision Medicines's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Praxis Precision Medicines (Praxis Precision Medicines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Praxis Precision Medicines Inc (NAS:PRAX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

99 High Street, 30th Floor, Boston, MA, USA, 02110

Website

https://www.praxismedicines.com

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.

Executives

Jill Desimone	director	C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Marcio Souza	officer: Chief Executive Officer	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Dean J Mitchell	director	C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Timothy Edwin Kelly	officer: Chief Financial Officer	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Lauren Mastrocola	officer: Principal Accounting Officer	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Alex Nemiroff	officer: General Counsel and Secretary	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Bsof Parallel Master Fund L.p.	10 percent owner	345 PARK AVENUE, NEW YORK NY 10154
Merit Ester Cudkowicz	director	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Jeffrey Chodakewitz	director	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL ST., SUITE 101, WATERTOWN MA 02472
Stefan Vitorovic	director	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Blackstone Holdings I/ii Gp L.l.c.	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
William D Young	director	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Stephen A Schwarzman	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Inc.	10 percent owner	345 PARK AVENUE, NEW YORK NY 10154
Blackstone Group Management L.l.c.	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154